[Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].

In a randomized cross-over study with 10 volunteers two different commercial preparations of allopurinol (Remid and standard) were tested by reversed-phase HPLC with respect to their pharmacokinetic behaviour. After a single p.o. dose of 300 mg allopurinol plasma elimination half-life of the major metabolite oxipurinol was found to be about 40 h with both preparations, calculated from the course of the plasma levels. This result confirms that a single daily dose of 300 mg allopurinol in non-retard formulation supports therapeutically sufficient circadian plasma levels.

RCT Entities:   Population Interventions Outcomes